Lilly Expands Retatrutide Access Amid Doctor Pushback

Eli Lilly and Company confirmed on August 3, 2026, that a defined group of patients can now apply for early access to its investigational obesity drug, retatrutide, ahead of FDA approval.¹ The company built the pathway after weeks of physician pressure that followed an earlier, single-patient case: in April, Lilly granted a 79-year-old patient special compassionate-use access to the drug, an arrangement STAT News first reported in June. A Lilly spokesperson said the company is "actively reviewing requests from health care providers" through the newly acknowledged program, which is open to patients who meet defined clinical criteria and cannot enroll in a clinical trial. Descriptions of those criteria vary slightly by outlet.

A source familiar with Lilly's program told STAT that qualifying patients must be 18 or older, unable to participate in a clinical trial, have refractory obesity with 2 or more serious complications, and have discussed all standard treatment options. Reuters reported similar criteria from a company spokesperson but specified that patients must have refractory obesity despite tolerating the highest approved dose of an obesity therapy, rather than simply having discussed standard options.² The discrepancy was not reconciled as of publication.

The Announcement Follows a Single-Patient Controversy

The move follows STAT's original report that Lilly granted the 79-year-old patient access to retatrutide in April, months before any broader access framework existed.¹ The application, filed by a senior clinician at the NIH, cited refractory obesity, obstructive sleep apnea, and pulmonary hypertension, and drew interest from top health officials. After STAT asked the White House whether the recipient was President Donald Trump, who turned 80 in June, a spokesperson said the application was not for the president. Democratic lawmakers have since pressed the administration for more detail on the recipient's identity.

Clinicians Described Weeks of Silence

Multiple physicians who separately sought compassionate-use access for their own patients told STAT they went weeks without a substantive response from Lilly. Spencer Nadolsky, DO, and Mike Albert, MD, both of the online obesity clinic Vineyard, said they applied for several patients who had not adequately responded to Lilly's approved therapy, Zepbound (tirzepatide). Nadolsky said one of his patients received only a preliminary qualification, and only after STAT contacted Lilly for comment. Angela Fitch, MD, FACP, MFOMA, DABOM, chief medical officer of the obesity clinic knownwell, said clinicians "are owed an explanation of some sort" about whether a formal program exists.

Other physicians, including Fatima Cody Stanford, MD, MPH, MPA, of Harvard Medical School and Gitanjali Srivastava, MD, FACP, FAAP, of Vanderbilt University Medical Center, said they are not yet pursuing compassionate use for their patients and want to see more retatrutide safety data before offering it outside a monitored trial setting. Stanford, a clinical investigator on Lilly's retatrutide trials, said she does not believe the company intended to extend access beyond the original patient and now must address a program it may not have planned to build.

Phase 3 Data Strengthen the Case for Approval

The scrutiny arrives as Lilly builds its regulatory case for retatrutide, a once-weekly agonist of the gastric inhibitory polypeptide, glucagon-like peptide-1, and glucagon receptors.³ In July, the company reported positive topline results from 2 pivotal phase 3 trials, TRIUMPH-2 (NCT05929079) and TRIUMPH-3 (NCT05882045). In TRIUMPH-2, adults with type 2 diabetes and obesity or overweight lost up to an average of 20.8% of body weight (49.6 lb) at 80 weeks on the highest dose, alongside A_1C reductions of up to 1.6 percentage points. In TRIUMPH-3, adults with severe obesity and established cardiovascular disease lost up to an average of 22.6% of their body weight (55.8 lb) at 80 weeks. Major adverse cardiovascular events occurred numerically less often with retatrutide than placebo, although the difference did not reach statistical significance. The most common adverse events across both trials were diarrhea, nausea, constipation, and decreased appetite. Lilly said it plans to submit a biologics license application for retatrutide to the FDA in the first quarter of 2027.

Questions About Scale and Transparency Remain

Even with defined criteria, the program's reach is likely to stay narrow relative to demand, since qualifying requires both a documented complication burden and, depending on the account, either maximum-dose treatment failure or discussion of standard options.^1,2 Fitch said she has not yet submitted an application and is still seeking details from Lilly on whether patients would need to visit a clinical trial site to receive treatment.¹ The announcement marks a striking shift for a company that had, until now, offered little public information about its compassionate-use process, according to STAT.

References

1. Lawrence L, Chen E. Eli Lilly to allow more patients to apply for special access to unapproved obesity drug. STAT. August 3, 2026. Accessed August 4, 2026. https://www.statnews.com/2026/08/03/eli-lilly-retatrutide-mystery-patient-doctors-seek-same-access-their-patients/
2. Sneha SK, Beasley D. Eli Lilly to offer early access to next-gen obesity drug to some patients. Reuters. August 3, 2026. Accessed August 4, 2026. https://www.reuters.com/legal/litigation/eli-lilly-offer-early-access-next-gen-obesity-drug-some-patients-2026-08-03/
3. Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional phase 3 obesity trials, delivering significant improvements in weight and A1C. News release. July 23, 2026. Accessed August 4, 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional